



Suite 424, 800-15355 24th Avenue,
Surrey BC V4A2H9

1-833-IZOCORP | www.izocorp.com

IZOTROPIC CORPORATION ANNOUNCES APPOINTMENT OF DR. JOHN MCGRAW TO ADVISORY BOARD

VANCOUVER, BC – February 13, 2020 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTC US: IZOZF) (FRA: 1R3) is pleased to announce the appointment of John McGraw MSc PhD to the Advisory Board.

Dr. McGraw brings over 20 years of technology and business development experience spanning several medical device and healthcare-related market segments and has created and implemented successful strategies for the commercialization of new technologies in medical devices, imaging and laboratory diagnostics and therapeutics.

In addition to his extensive entrepreneurial and consulting experience, Dr. McGraw has also provided executive leadership to two public companies. He was VP of Operations for Novadaq Technologies Inc. (NASDAQ: NCVQ), a medical device imaging company which was acquired by Stryker Corporation for US \$701M in 2017. He was also Senior Vice President Business Development & Strategy for CML HealthCare Inc (TSX:CLC), one of Ontario's leading providers of laboratory diagnostic services and Canada's largest provider of medical imaging services which was acquired by LifeLabs (owned by OMERS/Borealis) for CA\$1.2B in 2013.

The Company's Advisory Board is comprised of experts in medical physics, radiology, breast imaging, breast cancer screening, bioengineering and biotechnology. The addition of Dr. McGraw to the Advisory Board brings relevant market sector operating experience and executive level advisory to the Board of Directors.

The Company will also engage Dr. McGraw to provide ongoing consulting services related to product development, marketing, manufacturing, compliance, FDA filing processes and clinical trials. He will also represent the Company in financing and technology presentations.

Overall, Dr. McGraw brings a wealth of knowledge and contacts to the Company, along with highly relevant executive level strategic and operating experience in the medical imaging market sector. We look forward to having Dr. McGraw on our Advisory Board to provide leadership as we move toward final developments, regulatory approvals and commercialization of the Izotropic Breast CT Imaging System.

“Izotropic is developing an imaging device that will greatly enhance the detection of breast cancer with its superior 3D imaging capabilities, without the need for tissue compression and a scan that takes just 10 seconds. It is exciting to work with Izotropic and I look forward to helping advance this innovative technology that will have such a meaningful impact in breast cancer detection” said Dr. McGraw.

ON BEHALF OF THE BOARD

Robert Thast
Chief Executive Officer, Director

About Izotropic Corp.

Izotropic Corporation (the Company) and its wholly owned U.S. operating subsidiary, Izotropic Imaging Corp. have been established to commercialize the next generation of breast imaging technology for early diagnosis of breast



Suite 424, 800-15355 24th Avenue,
Surrey BC V4A2H9

1-833-IZOCORP | www.izocorp.com

cancer. The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires approximately 500 images, without painful breast compression, providing radiologists with fully 3D viewing of the scanned breast. Mammography scanning requires compression of the breast between 2 imaging plates, resulting in 2D images.

The Company has the exclusive license from the University of California, Davis (UC Davis) to commercialize the technology developed by principal founder and Company director Dr. John M. Boone and researchers at UC Davis. The license includes all intellectual property, trade secrets, patents and patent-pending applications that are the foundation of the Company's breast CT imaging platform.

Approximately \$20 million in research funding and over 15 years of research and development have been invested in developing this groundbreaking breast CT imaging technology. Research includes a current, fully funded \$2.9M U.S. clinical trial at UC Davis Medical Center.

The Company founders believe that this technology will be a disruptive entry to the market, overcoming many of the challenges faced by existing breast imaging modalities.

Phone: 1-833-IZOCORP

Email: info@izocorp.com Website:

izocorp.com